CRSP in “The Patent Cliff Sparks a Biotech Land Grab”
CRISPR Therapeutics AG
Commercial validation of CRISPR-based medicine increases the strategic value of the company's gene-editing platform and follow-on oncology and autoimmune programs.
CRSP impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to CRSP’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading CRSP impact map…
Price history, marked with story events
Oct 12, 2026 – Oct 19, 2026 · 6 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BULL side — Commercial validation of CRISPR-based medicine increases the strategic value of the company's gene-editing platform and follow-on oncology and autoimmune programs.
Read the full The Patent Cliff Sparks a Biotech Land Grab story